论文部分内容阅读
目的:观察塞来昔布作为增敏剂联合128Ⅰ粒子植入治疗肺癌的近期疗效.方法:将66例经病理确诊的肺癌患者行CT引导下的125Ⅰ例子植入治疗,随机分为两组(实验组33例,对照组33例),实验组在125Ⅰ粒子植入当天给予塞来昔布,对照组单纯行125Ⅰ粒子植入治疗.采用肿瘤局部控制率(完全缓解+部分缓解)作为疗效的评价标准.结果:实验组(125Ⅰ粒子植入联合塞来昔布放疗增敏剂)33例患者,完全缓解3例,部分缓解24例,无变化3例,进展3例;对照组(单纯125Ⅰ粒子植入)33例患者中,完全缓解1例,部分缓解19例,无变化10例,进展3例;总的有效率(完全缓解+部分缓解)比较差异有统计学意义(P＜0.05).结论:塞来昔布联合1125Ⅰ粒子植入治疗肺癌,具有较好的放射增敏作用,提高了肿块的局控率,副作用小、安全、有效.“,”Objective:To observe the short-term efficacy for celecoxib as a sensitization agent for 125Ⅰ particles implantation in the treatment of lung cancer.Methods:Sixty-six patients with lung cancer were treated by CT guided interstitial 125Ⅰparticles implantation.They were randomly divided into two groups (33 patients in test group,the other 33 in control group).The test group was given celecoxib on the same day of 125Ⅰ particles implantation.The control group was only implanted with 125Ⅰ particles.The local control of the tumor(complete relief+partial relief) was used as an evaluation standard of curative effect.Results:Among the 33 patients in the test group (125Ⅰ particles implanted with celecoxib as radiotherapy sensitization agent),3 patients had complete relief,24 patients had partial relief,3 patients had no effect and 3 patients had slight relief.The short-term effective rate was 81.8％.In the control group (33 cases with implanted 125Ⅰ particles only):1 patient had complete relief,19 patients had partial relief,3 patients had slight relief and 3 patients had no effect.The recent effective rate was 60.6％.The difference between the two groups was statistically significant (P＜0.05).Conclusion:The treatment of celecoxib combined with 125Ⅰ particles implantation for lung cancer has good radiotherapy sensitization effect.It improves the local control rate of tumor and has fewer side effects and is safe and effective.